Cannabidiol exerts antiinflammatory effects but maintains T effector memory cell differentiation in humans
Authors:
- Debora L. GischDGDebora L. Gisch
- Sachiko KoyamaSKSachiko Koyama
- Jumar EtkinsJEJumar Etkins
- Gerald C. SoGSGerald C. So
- Daniel J. FehrenbachDFDaniel J. Fehrenbach
- Ying-Hua ChengYCYing-Hua Cheng
- Evan RajadhyakshaEREvan Rajadhyaksha
- Kelsey McClaraKMKelsey McClara
- Mahla AsghariMAMahla Asghari
- Asif A. SharfuddinASAsif A. Sharfuddin
Open Access
- 18 November 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (1)
Abstract
BACKGROUND: Cannabidiol (CBD) is increasingly used for pain management, including in transplant recipients with limited analgesic options. Its immunomodulatory effects in humans are not well defined at a single-cell level at CBD steady state with concomitant tacrolimus treatment. METHODS: In a phase I ex vivo study, peripheral blood mononuclear cells from 23 participants who received oral CBD (Epidiolex) up to 5 mg/kg twice daily for 11 days were collected before CBD (pre-CBD) and at steady state (post-CBD). Lymphocytes were isolated and stimulated with anti-CD3/CD28 antibodies, with or without tacrolimus (5 ng/mL). Pharmacodynamic responses were assessed using CellTiter-Glo proliferation, single-cell and single-nucleus RNA sequencing, cytokine assays, and flow cytometry. Steady-state plasma concentrations of CBD were quantified via tandem mass spectrometry. RESULTS: We identified an increased proportion of T effector memory (TEM) cells post-CBD (22% increase), which correlated with CBD plasma concentrations ( R = 0.77, P = 0.01). CBD reduced proliferation of T (37% decrease) and CD70 hi B (17% decrease) lymphocytes with additive immunosuppressive effects to tacrolimus. Single-cell RNA sequencing revealed reduced IL2 and TNF signaling and altered receptor-ligand networks in TEM cells. Post-CBD cytokine assays revealed elevated proinflammatory IL-6 protein levels and antiinflammatory IL-10 levels, with reduced TNF-α, LTA, and IL-2. In flow cytometry, the proportion of TEM and TEMRA cells increased post-CBD with tacrolimus. CONCLUSION: CBD exerts mixed immunomodulatory effects in humans, combining antiproliferative and pro- and antiinflammatory responses. Understanding the clinical safety of CBD use is important given the paucity of pain control options available for immunocompromised transplant populations. TRIAL REGISTRATION: ClinicalTrials.gov NCT05490511 FUNDING: NIH/National Center for Complementary and Integrative Health (R01AT011463); NIH/National Institute of General Medical Sciences (NIGMS) (R35GM145383); Intramural Research Program of the NIH; NIH/NIGMS (T32GM008425).Keywords
Funding Information
- NIH/NCCIH (R01AT011463)
- National Center for Complementary and Integrative Health (R01AT011463)
This publication has 55 references indexed in Scilit:
- A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and TacrolimusClinical Pharmacology & Therapeutics, 2024
- High‐Dimensional Bayesian Semiparametric Models for Small Samples: A Principled Approach to the Analysis of Cytokine Expression DataBiometrical Journal, 2024
- Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammationCell Reports, 2023
- Pharmacokinetic Drug‐Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer TrialClinical Pharmacology in Drug Development, 2023
- Integrated analysis of multimodal single-cell dataCell, 2021
- Separate signaling events control TCR downregulation and T cell activation in primary human T cellsImmunity, Inflammation and Disease, 2020
- Cannabidiol induced apoptosis in human monocytes through mitochondrial permeability transition pore-mediated ROS productionFree Radical Biology and Medicine, 2018
- Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and DifferentiationJournal of Neuroimmune Pharmacology, 2017
- Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activationCellular Immunology, 2017
- The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT)Biochemical Pharmacology, 2008